(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 January 2022 (06.01.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/005932 A1

(51) International Patent Classification:
A61P 11/00 (2006.01) *A61P 1/00* (2006.01)
A61K 9/00 (2006.01) *A61K 47/36* (2006.01)

(21) International Application Number:
PCT/US2021/039310

(22) International Filing Date:
28 June 2021 (28.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/045,947 30 June 2020 (30.06.2020) US

(71) Applicant: **GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC** [US/US]; 251 Little Falls Drive, Wilmington, DE 19808 (US).

(72) Inventors: **ENGLAND, Kenneth Earl**; 1211 Sherwood Avenue, Richmond, VA 23220 (US). **PATEL, Shivangi Akash**; 1211 Sherwood Avenue, Richmond, VA 23220 (US). **YANG, Chue Hue**; 288 Mazeppa Road, Mooresville, NC 28115 (US).

(74) Agent: **DODSON, Christopher S.** et al.; Glaxosmithkline, Global Patents, UP4110, 1250 South Collegeville Road, Collegeville, PA 19426 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

WO 2022/005932 A1

(54) Title: LOZENGE

(57) Abstract: A lozenge comprises 1.4-18% by weight pectin; 78-88% by weight sweetener; 0.1-15% of an organic acid; and 10-19% by weight of water. A method of treating sore throats comprises applying a lozenge of claim 1 to an oral cavity of a patient in need; and dissolving the lozenge over a period of at least 5 minutes.